Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis

被引:28
|
作者
Lv, Lingshuang [1 ]
Li, Tiecheng [2 ]
Xu, Kun [1 ]
Shi, Peiyi [1 ]
He, Biyu [1 ]
Kong, Weimin [3 ]
Wang, Jianming [1 ]
Sun, Jian [3 ]
机构
[1] Nanjing Med Univ, Sch Publ Hlth, Key Lab Infect Dis, Dept Epidemiol, 101 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China
[2] Fourth Peoples Hosp Lianyungang City, Dept TB, Lianyungang, Peoples R China
[3] First Peoples Hosp Yancheng City, Dept Thorac Surg, 166 Yulong West Rd, Yancheng 224001, Peoples R China
来源
基金
中国国家自然科学基金;
关键词
multidrug-resistant tuberculosis; sputum smear conversion; sputum culture conversion; treatment outcome; prognosis; CULTURE CONVERSION; METAANALYSIS; PREDICTORS;
D O I
10.2147/IDR.S153499
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Purpose: Multidrug-resistant tuberculosis (MDR-TB) requires long-term treatment, has a high fatality rate, and constitutes a global threat. Earlier detection of treatment failure is required to predict therapeutic efficacy. Patients and methods: We enrolled MDR-TB patients consecutively from January 2011 through December 2012 in Lianyungang, China. Sputum smear microscopy tests and sputum cultures were performed once a month for the first 6 months following initiation of antituberculosis treatment and once every 2 months thereafter until the end of therapy. The sensitivity, specificity and area under the receiver operating characteristic curve (AUC) were used with a 95% CI to estimate the role of sputum bacteriology conversion in predicting treatment outcomes. Results: Among the 92 MDR-TB patients enrolled in this study, 40.2% had poor treatment outcomes. The median initial sputum bacteriology conversion time was 1 month. Patients having 2-month sputum smear conversions (adjusted odds ratio [OR]: 7.19, 95% CI: 2.60-19.84) or culture conversions (adjusted OR: 2.88, 95% CI: 1.11-7.45) were more likely to experience good outcomes. The sensitivity and specificity obtained when using two-month sputum smear conversions to predict treatment outcomes were 67.6% (95% CI: 50.2-82.0) and 76.4% (95% CI: 63.0-86.8), respectively. The sensitivity and specificity obtained when using 2-month culture conversions to predict treatment outcomes were 48.6% (95% CI: 32.0-65.6) and 74.5% (95% CI: 61.0-85.3), respectively. The AUC for two-month smear conversions was 0.72 (95% CI: 0.62-0.81), significantly higher than that obtained for 2-month culture conversions (0.62, 95% CI: 0.52-0.72) (X-2 = 4.18, P = 0.041). Conclusion: The prognoses of MDR-TB patients displaying persistent sputum positivity were inferior to those for whom sputum bacteriology conversion was observed. Thus, sputum smear conversion results obtained 2 months after treatment initiation may provide a potential means for predicting MDR-TB treatment outcomes.
引用
收藏
页码:147 / 154
页数:8
相关论文
共 50 条
  • [41] Delamanid in the treatment of multidrug-resistant tuberculosis
    Gupta, R.
    Wells, C. D.
    Hittel, N.
    Hafkin, J.
    Geiter, L. J.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2016, 20 (12) : S33 - S37
  • [42] Treatment of multidrug-resistant tuberculosis in Taiwan
    Suo, J
    Yu, MC
    Lee, CN
    Chiang, CY
    Lin, TP
    CHEMOTHERAPY, 1996, 42 : 20 - 23
  • [43] Effective multidrug-resistant tuberculosis treatment
    Nierengarten, MB
    LANCET INFECTIOUS DISEASES, 2003, 3 (03): : 118 - 118
  • [44] Surgery in the treatment of multidrug-resistant tuberculosis
    Pomerantz, M
    Brown, JM
    CLINICS IN CHEST MEDICINE, 1997, 18 (01) : 123 - &
  • [45] Diagnosis and treatment of multidrug-resistant tuberculosis
    Kang, Young Ae
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2014, 57 (01): : 27 - 33
  • [46] Treatment of multidrug-resistant tuberculosis in Indonesia
    Hadiarto, M
    Tjandra, YA
    Hudoyo, A
    CHEMOTHERAPY, 1996, 42 : 24 - 29
  • [47] TREATMENT AND PREVENTION OF MULTIDRUG-RESISTANT TUBERCULOSIS
    COHN, DL
    ISEMAN, MD
    RESEARCH IN MICROBIOLOGY, 1993, 144 (02) : 150 - 153
  • [48] Clofazimine for the treatment of multidrug-resistant tuberculosis
    Lange, C.
    Chesov, D.
    Heyckendorf, J.
    CLINICAL MICROBIOLOGY AND INFECTION, 2019, 25 (02) : 128 - 130
  • [49] The treatment of multidrug-resistant tuberculosis in Turkey
    Tahaoglu, K
    Törün, T
    Sevim, T
    Ataç, G
    Kir, A
    Karasulu, L
    Özmen, I
    Kapakli, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03): : 170 - 174
  • [50] Treatment and prevention of multidrug-resistant tuberculosis
    Bastian, I
    Colebunders, R
    DRUGS, 1999, 58 (04) : 633 - 661